The non-linear threshold association between aspirin use and esophageal adenocarcinoma: Results of a dose-response meta-analysis

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 3, 2014, Pages 278-284

  Xiaohua, Ye ^a,b   Zhenjiang, Yao ^a   Weidong, Liu ^a   Pengcheng, Xun ^c   Sidong, Chen ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Aspirin; Epidemiology; Esophageal cancer; Nonsteroidal anti inflammatory drugs; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; DATA BASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG USE; EMBASE; ESOPHAGEAL ADENOCARCINOMA; HUMAN; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; ADENOCARCINOMA; CHEMICALLY INDUCED; ESOPHAGEAL NEOPLASMS; NONLINEAR SYSTEM; PROCEDURES;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; NONLINEAR DYNAMICS; OBSERVATIONAL STUDY AS TOPIC;

EID: 84895480329     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3560     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. doi:10.3322/caac.20107.
2. Steevens J, Botterweck AA, Dirx MJ, et al. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol 2010; 22: 669-678. doi:10.1097/MEG.0b013e32832ca091.
3. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009; 101: 855-859. doi:10.1038/sj.bjc.6605246.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289. doi:10.1001/jama.265.10.1287.
5. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53. doi:10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO;2-U.
6. Jankowski JA, Odze RD. Biomarkers in gastroenterology: between hope andhype comes histopathology. Am J Gastroenterol 2009; 104: 1093-1096. doi:10.1038/ajg.2008.172.
7. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507. doi:10.1016/S1470-2045(09)70035-X.
8. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer. JAMA 2005; 294: 47-55. doi:10.1001/jama.294.1.47.
9. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-1415. doi:10.1093/annonc/mds113.
10. Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009; 100: 551-557. doi:10.1038/sj.bjc.6604880.
11. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56. doi:10.1053/gast.2003.50008.
12. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012; 142: 442-452. doi:10.1053/j.gastro.2011.11.019.
13. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med 2009; 6: e1000097. doi:10.1371/journal.pmed.1000097.
14. Wells GA, Shea B, O'Connel ID, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. Ottawa Health Research Institute: Ottawa, Ontario, 2010. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. (accessed 9 November 2011).
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560. doi:10.1136/bmj.327.7414.557.
16. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006; 6: 40-57. doi:10.1111/j.1360-0443.2011.03772.x.
17. Rota M, Bellocco R, Scotti L, et al. Random-effects meta-regression models for studying nonlinear dose-response relationship, with an application to alcohol and esophageal squamous cell carcinoma. Stat Med 2010; 29: 2679-2687. doi:10.1002/sim.4041.
18. Orsini N, Li R, Wolk A, et al. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012; 175: 66-73. doi:10.1093/aje/kwr265.
19. Chu HA, Crawford-Brown DJ. Inorganic arsenic in drinking water and bladder cancer: a meta-analysis for dose-response assessment. Int J Environ Res Public Health 2006; 3: 316-322. doi:10.3390/ijerph2006030039.
20. Ye X, Fu J, Yang Y, et al. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One 2013; 8: e71522. DOI: 10.1371/journal.pone.0071522
21. Irving HM, Samokhvalov AV, Rehm J. Alcohol as a risk factor for pancreatitis. A systematic review and meta-analysis. JOP 2009; 10: 387-392.
22. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7: 889-894. doi:10.1002/sim.4780070807.
23. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463. doi:10.1111/j.0006-341X.2000.00455.x.
24. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102.
25. Jayaprakash V, Menezes RJ, Javle MM, et al. Regular aspirin use and esophageal cancer risk. Int J Cancer 2006; 119: 202-207. doi:10.1002/ijc.21814.
26. Fortuny J, Johnson CC, Bohlke K, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 2007; 5: 1154-1159. doi:10.1016/j.cgh.2007.05.022.
27. Figueroa JD, Terry MB, Gammon MD, et al. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control 2009; 20: 361-368. doi:10.1007/s10552-008-9250-6.
28. Duan L, Wu AH, Sullivan-Halley J, et al. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2008; 17: 126-134. doi:10.1158/1055-9965.EPI-07-0664.
29. Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006; 66: 4975-4982. doi:10.1158/0008-5472.CAN-05-4253.
30. Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012; 24: 917-923. doi:10.1097/MEG.0b013e3283543f01.
31. Sadeghi S, Bain CJ, Pandeya N, et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008; 17: 1169-1178. doi:10.1158/1055-9965.
32. Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS ONE 2013; 8: e57578.DOI: 10.1371/journal.pone.0057578
33. Yu HP, Shi LY, Lu WH, et al. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol 2004; 19: 638-42. doi:10.1111/j.1440-1746.2004.03345.x.
34. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
35. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66. doi:10.1093/jnci/94.4.252.
36. Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci 2008; 65: 1295-301. doi:10.1007/s00018-008-7511-x.
37. Zampeli E, Karamanolis G, Morfopoulos G, et al. Increased expression of VEGF, COX-2, and Ki-67 in Barrett's esophagus: does the length matter? Dig Dis Sci 2012; 57: 1190-6. doi:10.1007/s10620-011-1990-6.
38. Majka J, Rembiasz K, Migaczewski M, et al. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects. J Physiol Pharmacol 2010; 61: 409-18.
39. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-6. doi:10.1111/j.1572-0241.2001.03599.x.
40. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-96. doi:10.1016/S0016-5085(00)70254-X.
41. Morgan GP, Williams JG. Inflammatory mediators in the oesophagus. Gut 1994; 35: 297-8. doi:10.1136/gut.35.3.297.
42. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86. doi:10.1136/bmj.324.7329.71.
43. Huang ES, Strate LL, Ho WW, et al. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One 2010; 5: e15721. DOI:10.1371/journal.pone.0015721
44. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41. doi:10.1016/S0140-6736(10)62110-1.
45. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005; 6: 945-52. doi:10.1016/S1470-2045(05)70431-9.
46. Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 1299-304. doi:10.1016/j.cgh.2009.06.001.
47. Tsibouris P, Hendrickse MT, Isaacs PE. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther 2004; 20: 645-55. doi:10.1111/j.1365-2036.2004.02150.x.
48. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010; 138: 2260-6. doi:10.1053/j.gastro.2010.02.045.
49. Das D, Ishaq S, Harrison R, et al. Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol 2008; 103: 1079-89. doi:10.1111/j.1572-0241.2008.01790.x.
50. Ishikawa S, Inaba T, Mizuno M, et al. Incidence of serious upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs in Japan. Acta Med Okayama 2008; 62: 29-36.